AFLIBERCEPT

Brand name:

• Eylea®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

BAYER AUSTRALIA LTD

Condition/indication:
(therapeutic use)

• Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New PBS listing (–)

Comment:

--

Other PBAC consideration:

• AFLIBERCEPT

Submission received for:

May 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 10/05/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

02/07/2024

Lodgement of required documentation:

11/07/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 14/08/2024

Status:

Finalised

Government processes:

Commenced on 23/08/2024

Medicine listed on the PBS:

01/10/2024 (see PBS schedule)